Low-dose aminoglutethimide therapy without glucocorticoid administration. Clinical and hormonal findings.
Eleven postmenopausal patients with advanced breast cancer were assessed for their response and endocrine changes to low-dose aminoglutethimide (250 mg twice a day) therapy without steroid administration. In 7 cases an objective response was registered; 1 patient had a stabilization of the disease lasting for 9 months. Significant falls in plasma estrogen and rises in plasma androgen levels were observed, while those of cortisol and ACTH remained essentially unchanged. No serious side effects occurred.
Kahán
Z
Z
Department of Radiology, A. Szent-Györgyi Medical University, Szeged, Hungary.
Tóth
I
I
Vecsernyés
M
M
D000368:Aged; D000616:Aminoglutethimide / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage; D006728:Hormones / Q000097:blood*; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000097:blood / Q000188:drug therapy*
D005938:Glucocorticoids; D006728:Hormones; D000616:Aminoglutethimide